36 results about "Bevacizumab" patented technology

The invention belongs to the technical field of medical diagnosis, and discloses a marker for evaluating the curative effect of treating hepatocellular carcinoma by combining TACE with Czodili monoclonal antibody and bevacizumab, and a construction method and application of an FAAP prognostic scoring model. The invention develops and verifies an FAAP prognostic scoring system, and a novel composite model integrates four indexes of fibrin degradation product / cholinesterase ratio * 1000 (FCR), aspartate aminotransferase (AST), alpha fetoprotein (AFP) and portal vein tumor thrombus (PVTT), and is used for predicting the survival condition of uHCC patients subjected to TACE-Czodimab-bevacizumab triple therapy. The tool has an instant clinical value, can optimize patient selection, guides adaptive treatment upgrading, and provides a standardized curative effect evaluation basis for a clinical test for exploring a TACE-immunotherapy-anti-angiogenesis combined scheme.

The present application relates to the technical field of medicine, in particular to the application of gansix triol A in the preparation of a drug for treating gastric cancer and / or non-small cell lung cancer, gansix triol A plays an anti-gastric cancer role by selectively inhibiting the proliferation of gastric cancer MGC-803 cells and inhibiting angiogenesis, the mechanism involves inhibiting the VEGF / VEGFR2 signal pathway and inducing cell apoptosis; the mechanism of gansix triol A in inhibiting the VEGF / VEGFR2 signal pathway is similar to that of bevacizumab; gansix triol A plays an anti-non-small cell lung cancer role by selectively inhibiting the proliferation of non-small cell lung cancer A549 cells, the mechanism involves inhibiting the MAPK / ERK signal pathway and inducing cell apoptosis. The present application finds that the cytotoxic activity of gansix triol A on MGC-803 cells and A549 cells is significantly stronger than that of tanshinone IIA; gansix triol A has an anti-tumor effect of "one drug with double targets, double inhibition" and "high efficiency and low toxicity".

The invention relates to the technical field of biological medicines, and particularly discloses an application of Dehydrovomigol sensitized bevacizumab in treatment of cervical cancer. The invention further relates to a preparation method of the Dehydrovomigol sensitized bevacizumab. Compared with a bevacizumab single drug, the effect of the bevacizumab on growth and proliferation inhibition, invasion blocking and angiogenesis inhibition of cervical cancer cells can be remarkably enhanced by combining the Dehydrovomifolol, and the drug resistance of the bevacizumab is reversed. In different experimental models, the Q value of the combination scheme is greater than or equal to 1.15, and the stable synergistic anti-cervical cancer effect is shown. Dehydrovomifolol realizes the effect of enhancing the anti-cervical cancer activity of the bevacizumab by virtue of triple mechanisms of reversing drug resistance, enhancing anti-angiogenesis and regulating an immune microenvironment. According to the combination scheme, the anti-cervical cancer curative effect can be improved, the clinical medication dosage of bevacizumab is reduced, the occurrence risk of toxic and side effects such as hypertension and proteinuria is reduced, and a novel, safe and efficient treatment strategy is provided for cervical cancer treatment.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administering to a metastatic colorectal cancer patient an effective amount of a PLK1 inhibitor (for example, onvansertib) and an effective amount of bevacizumab, wherein the patient has not received any treatment comprising bevacizumab within at least three months prior to the administration of the PLK1 inhibitor and bevacizumab in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

The invention provides a nano embolism microsphere based on a magnetocaloric effect and a preparation method and application thereof, and relates to the field of medicines. According to the nano embolization microsphere, mesoporous ferroferric oxide is used as a carrier, and rificiguat and bevacizumab are loaded at the same time. The preparation method has the beneficial effects that the magnetic nano embolism microsphere system is constructed for the first time and is combined with the magnetocaloric effect; according to the invention, the embolism system of the magnetic nano-microsphere loaded rificiguat and bevacizumab is constructed for the first time; compared with an embolism agent for independently embolizing the blood vessel, the nano embolism microsphere disclosed by the invention also plays a role in killing residual tumor cells; compared with an uncontrollable embolism agent, the nano embolism microsphere disclosed by the invention can be used for accelerating drug release in an alternating magnetic field and a slightly acidic environment.

A single-cell transcriptome-guided multimodal synergistic injectable magnetically responsive biomimetic hydrogel system, its preparation method, and its application are described. This hydrogel platform is a three-level composite system of "matrix-microsphere-nanoparticle": the primary structure is a photocrosslinked methacryloyl hyaluronic acid three-dimensional network matrix; the secondary structure is GelMA microspheres loaded with MTPT nanoparticles prepared by microfluidic control; and the tertiary structure consists of bevacizumab and magnetite nanoparticles dispersed in the HAMA matrix. The MTPT nanoparticles have a mesoporous silica core, which is sequentially coated with temozolomide, a polydopamine coating, and a T7 targeting peptide. Under the activation of an alternating magnetic field, Fe3O4 generates a magnetothermal effect, which not only achieves local hyperthermia but also accelerates the time-sequential release of bevacizumab and MTPT, synergistically exerting the effects of chemotherapy, anti-angiogenic therapy, and hyperthermia.

To provide pharmaceutical compositions for treating solid tumor, in particular, glioblastoma multiforme (GBM).SOLUTION: Provided herein is a pharmaceutical composition for use in a method for retarding progression of brain tumor, where the composition comprises a therapeutical effective dose of F16, that is, isoindole (1, 3-dioxy-2, 3-dihydro-1H-isoindol-4-yl)-amide and a therapeutically effective dose of a chemotherapeutic agent in a pharmaceutical carrier, where the brain tumor is glioblastoma multiforme, and the chemotherapeutic agent is temozolomide (TMZ) or bevacizumab (BVZ) or similar agent.SELECTED DRAWING: Figure 1

The application discloses a BICI scoring system for predicting the curative effect of immunotherapy for metastatic colorectal cancer and application thereof, and belongs to the technical field of biological medicine. The BICI scoring system is based on immunohistochemical detection, integrates four dimensions of angiogenesis, immune checkpoints, TGF-beta signal and immune activation, and is calculated by a formula IHC-BICI=VEGFA+PD-L2+TGFB1x2-CD8 score. Taking 4 points as a cut point, BICI-High and BICI-Low are divided, and a bevacizumab combined with an immune checkpoint inhibitor treatment benefit population is accurately screened. The application also discloses a detection kit containing four specific antibodies, application thereof and a treatment decision method. The scoring system of the application only needs conventional IHC detection, has low cost, excellent prediction effect, is suitable for second-line and above treatment and clinical stratification of MSS / pMMR type metastatic colorectal cancer, and has important clinical application value.

The present invention belongs to the technical field of hydrogel preparations, and specifically relates to a dual-responsive hydrogel, a preparation method, and an application thereof. The present invention synthesizes a cross-linked polycationic hydrogel composed of phenylboronic acid-modified sodium alginate, a protocatechuic acid-polyethyleneimine graft polymer, and bevacizumab sustained-release nanoparticles, referred to as a dual-responsive OSPPB hydrogel. This hydrogel blocks neurovascularization at the osteochondral interface by locally clearing extracellular RNA and releasing bevacizumab, thereby alleviating OA pain and disease progression.

To provide an ophthalmic composition of bevacizumab.SOLUTION: Provided is an ophthalmic composition of bevacizumab; a. herein, the limit of Bacterial Endotoxins Test (BET) is within the range of 0.001 to 0.4EU / mg, preferably within the range of 0.001 to 0.2Eu / mg, and more preferably within the range of 0.001 to 0.16Eu / mg; b. herein, a particulate substance is as follows; 1 to 50 particles≥diameter 10 μm per iv.ml, 0 to 5 particles≥diameter 25 μm per v.ml, and 0 to 2 particles≥diameter 50 μm per vi.ml; and c. herein, the composition has an aggregate of 0.1 to 5%, more preferably 0.1 to 4%, and most preferably 0.1 to 3.5% for 2 to 3 years, preferably for 2 to 2.5 years, and most preferably for 2 years.SELECTED DRAWING: None

To provide effective cancer treatments. [Solution] The present invention provides a cancer treatment method that combines a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody), and standard therapy (e.g., combination therapy of FOLFOX therapy with bevacizumab or cetuximab for unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a reduced-dose regimen for pancreatic cancer with distant metastases).

Disclosed are kits and methods for detecting whether a patient with metastatic colorectal cancer should receive AVASTIN® (bevacizumab) in addition to chemotherapy.

The application provides application of bevacizumab in preparation of a medicine for inhibiting hemorrhagic lesions of cerebral vascular malformations, and belongs to the technical field of medicine application. The application firstly discovers and proves by experiments that bevacizumab can be used for binding free VEGF molecules in serum of a patient with a cavernous cerebral vascular malformation, thereby inhibiting a VEGF path, and having obvious inhibiting effect on symptomatic hemorrhagic lesions of the cavernous cerebral vascular malformation, and developing a new use of bevacizumab, and providing a new selection of drug treatment for the patient with the cavernous cerebral vascular malformation.

The invention discloses a drug-loaded microgel-gel sustained-release dressing as well as a preparation method and application of the drug-loaded microgel-gel sustained-release dressing. The dressing comprises a drug microgel phase loaded by GelMA microspheres and a hydrogel shell phase formed by copolymerizing CSMA and a double-bond-containing micromolecule cross-linking agent, and can be polymerized and cured in situ through ultraviolet light. The carried medicine comprises one of bevacizumab, triamcinolone acetonide and fluorouracil, and multi-medicine synergistic slow release is achieved. The dressing provided by the invention has good biocompatibility, degradability, shape adaptability and slow release performance, can significantly improve local drug concentration, reduce administration frequency and improve patient compliance, and is suitable for treatment and repair of keloid.

The invention belongs to the technical field of organ-like models, and particularly discloses an FET vascularized colorectal cancer organ-like model for evaluating the treatment effect of bevacizumab. The FET vascularized colorectal cancer organoid model is formed by co-culturing human colorectal cancer organoid, vascular endothelial cells (HUVEC-GFP) and hepatic stellate cells (fibroblasts and simulated liver metastasis environment), and is constructed through the steps of separating the human colorectal cancer organoid, preparing a 3D culture support mixture, co-culturing the cells and dynamically culturing. By integrating vascular endothelial cells, hepatic stellate cells and a dynamic flow environment, the limitation of an existing model is overcome, and the treatment effect of bevacizumab is evaluated more accurately. By simulating physiological angiogenesis, liver metastasis microenvironment and hemodynamics, predictability and reliability of drug screening are improved.

The application provides a bevacizumab Fab antibody, a detection reagent and a preparation method and application thereof, and belongs to the technical field of drug detection. The bevacizumab Fab antibody comprises a coating antibody Beva-7E1 and an enzyme-labeled antibody Beva-6C11; the coating antibody Beva-7E1 is produced by a hybridoma cell strain Beva-7E1 (the preservation number is CGMCC No.46305), and the enzyme-labeled antibody Beva-6C11 is produced by a hybridoma cell strain Beva-6C11 (the preservation number is CGMCC No.46306). The bevacizumab Fab antibody and the detection reagent thereof can be used for detecting the free blood drug concentration of bevacizumab with high specificity, high sensitivity, simplicity, rapidness and high automation degree.

The invention focuses on developing final ophthalmic dosages based on Sildenafil associated with bevacizumab, known for its retino-protective properties, aimed to preserve and improve visual functions, particularly in patients with retinal degenerative disease specially for the dry form of macular degeneration

The application belongs to the field of protein purification, and relates to a method for preparing bevacizumab, comprising the steps of affinity chromatography, virus inactivation, deep filtration, composite anion exchange chromatography, cation exchange chromatography and the like.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administering to a metastatic colorectal cancer patient an effective amount of a PLK1 inhibitor (for example, onvansertib) and an effective amount of bevacizumab, wherein the patient has not received any treatment comprising bevacizumab within at least three months prior to the administration of the PLK1 inhibitor and bevacizumab in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

The invention belongs to the technical field of medicines, and discloses a method for promoting drug resistance of triple negative breast cancer bevacizumab by driving IGF2BP3 lactic acid modification through PARK7, and milk acylation modification (IGF2BP3-K76lac) of lysine at the 76th site of IGF2BP3 protein is a key driving factor of drug resistance of bevacizumab. The overexpression of the IGF2BP3-K76lac can obviously enhance the drug resistance of the bevacizumab, and the overexpression of the IGF2BP3-K76lac is verified in both in-vitro experiments and in-vivo models. From the perspective of a molecular mechanism, the milk acylation modification at the IGF2BP3K76 site can enhance the binding capacity of the IGF2BP3K76 site and m6A modified FSP1 mRNA, so that the expression level of FSP1 is up-regulated, and finally the cells are endowed with ferroptosis resistance. By blocking the IGF2BP3-K76lac, ferroptosis induced by bevacizumab can be remarkably enhanced, the antioxidant defense mechanism of an organism is destroyed, and tumor growth is inhibited. In addition, PARK7 functions as a milk acyltransferase, and enhances the binding ability of IGF2BP3-K76lac to promote the function thereof. And finally, the blocking antibody targeting IGF2BP3-K76lac is proved to have a synergistic effect with the bevacizumab, so that the sensitivity of the bevacizumab is effectively recovered.

The application relates to the technical field of biological medicine, and particularly discloses a bifunctional fusion protein and application thereof in treating retinal degenerative diseases. The fusion protein is named Beva-1L, which is formed by fusing an amino acid sequence of human brain-derived neurotrophic factor (BDNF) with a light chain of an anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab. The fusion protein can simultaneously inhibit VEGF-mediated pathological angiogenesis and provide neurotrophic support, and is used for treating retinal degenerative diseases such as diseases simulated by an rd10 mouse model. Experiments show that the amplitude of a retinal electrogram (ERG) of the rd10 mouse can be significantly improved by injecting the Beva-1L, and the effect is equivalent to that of a positive drug. The application also relates to a coding gene, an expression vector, a host cell, a pharmaceutical composition of the fusion protein and application thereof. The fusion protein has a bifunctional synergistic effect, and provides a new treatment strategy for retinal degenerative diseases.

The invention discloses a bispecific antibody targeting heterogeneous macrophages, and relates to the field of biological medicines. According to the present invention, bevacizumab is adopted as a parent antibody skeleton, antibody arms targeting CD16 are arranged on the N end side, antibody arms targeting CD163 are located on the C end side, knob mutation (K322A and T366W) is introduced into the heavy chain CH3 structural domain targeting CD16, three complementary hole mutations (T366S, L368A and Y407V) are introduced into the heavy chain CH3 structural domain targeting CD163, and cysteine residues are inserted into the S354 site of the knob chain and the Y349 site of the hole chain; variable regions (V regions) targeting CD16 and CD163 are connected in series through a (G4S) 3 flexible linker and then fused with respective constant regions (C regions). The double-antibody architecture disclosed by the invention realizes collaborative optimization in structural stability, double-antigen binding specificity, macrophage targeting and functional activity, provides an efficient and safe novel candidate drug for targeted therapy of related diseases, and has important clinical transformation value and application prospect.

The present application belongs to the technical field of intelligent medical treatment, and particularly relates to a RAS, BRAF gene wild type colorectal cancer liver metastasis patient curative effect prediction model based on image group characteristics and application thereof. The present application successfully constructs a model for realizing curative effect prediction of RAS, BRAF gene wild type colorectal cancer liver metastasis patients receiving bevacizumab combined with chemotherapy treatment in the late first line based on CT image group characteristics before treatment: the enhanced CT image group data before initial treatment of patients with advanced colorectal cancer liver metastasis at the time of initial diagnosis is collected, 7 image group characteristics are obtained by using 1000 times Lasso-Logistic analysis, and an image group prediction model is constructed by using a multi-factor logistic regression method. The model constructed by the present application has important clinical application and popularization value from the clinical actual problem.

The present application relates to methods of stimulating an immune response in a subject by administering to the subject (i) an antibody that binds human IL-27 or an antigen binding portion thereof (an anti-IL-27 antibody), (ii) toripalimab, and (iii) bevacizumab. Methods of treating a cancer by administering (i) an antibody that binds human IL-27 or an antigen binding portion thereof (an anti-IL-27 antibody), (ii) toripalimab, and (iii) bevacizumab are provided.

The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (e.g., bevacizumab) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as cervical cancer.

The efficacy and indication of bevacizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

The invention relates to a vesicle loaded with Bevacizumab and a preparation method and application thereof.The vesicle is formed by mixing cell membrane nano vesicles and platelet membrane nano vesicles which encode TIGIT genes, the mass ratio of the cell membrane nano vesicles to the platelet membrane nano vesicles is (1-10): 1, the vesicles encapsulate Bevacizumab, and the vesicles can specifically target liver and TZ, inhibit neovascularization and improve the activity of TZ. And the anti-tumor function of the CD8 + T cells is recovered. Research results show that BevatTPNV can effectively inhibit liver metastasis after MWA. Compared with a control group, the intrahepatic metastasis load is reduced by about 10 times, and the survival rate of mice within 70 days reaches 50%. The work is expected to establish a new standard treatment mode, and the combined immunotherapy after hepatic metastatic tumor ablation can be thoroughly changed.

A use of Apicidin combined with Bevacizumab in preparing a drug for treating cervical cancer is provided. Studies have shown that Apicidin increases the sensitivity of cervical cancer cells to the targeted drug Bevacizumab. The combined use of Apicidin and Bevacizumab can more effectively inhibit the growth of cervical cancer cells and enhance the ability to induce apoptosis of cervical cancer cells, showing a good synergistic effect. Therefore, the use prospects of Apicidin combined with the targeted drug Bevacizumab are huge, which provides a more effective and feasible solution for the clinical treatment of cervical cancer, and proposes a new theoretical basis for the combined treatment of clinical cervical cancer recurrence and drug resistance.

Treatment combinations are provided for FOLR1-binding immunoconjugates (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), platinum-based agents, and / or doxorubicin. Methods for administering said combinations to treat cancers, such as ovarian cancer, with increased clinical efficacy and / or reduced toxicity are also provided.